Fukuyama muscular dystrophy (FCMD; MIM253800), one of the most common autosomal recessive disorders in Japan, was the first human disease found to result from ancestral insertion of a SINE-VNTR-Alu (SVA) retrotransposon into a causative gene [1] [2] [3] . In FCMD, the SVA insertion occurs in the 39 untranslated region (UTR) of the fukutin gene. The pathogenic mechanism for FCMD is unknown, and no effective clinical treatments exist. Here we show that aberrant messenger RNA (mRNA) splicing, induced by SVA exon-trapping, underlies the molecular pathogenesis of FCMD. Quantitative mRNA analysis pinpointed a region that was missing from transcripts in patients with FCMD. This region spans part of the 39 end of the fukutin coding region, a proximal part of the 39 UTR and the SVA insertion. Correspondingly, fukutin mRNA transcripts in patients with FCMD and SVA knock-in model mice were shorter than the expected length. Sequence analysis revealed an abnormal splicing event, provoked by a strong acceptor site in SVA and a rare alternative donor site in fukutin exon 10. The resulting product truncates the fukutin carboxy (C) terminus and adds 129 amino acids encoded by the SVA. Introduction of antisense oligonucleotides (AONs) targeting the splice acceptor, the predicted exonic splicing enhancer and the intronic splicing enhancer prevented pathogenic exontrapping by SVA in cells of patients with FCMD and model mice, rescuing normal fukutin mRNA expression and protein production. AON treatment also restored fukutin functions, including O-glycosylation of a-dystroglycan (a-DG) and laminin binding by a-DG. Moreover, we observe exon-trapping in other SVA insertions associated with disease (hypercholesterolemia 4 , neutral lipid storage disease 5 ) and human-specific SVA insertion in a novel gene. Thus, although splicing into SVA is known [6] [7] [8] , we have discovered in human disease a role for SVA-mediated exon-trapping and demonstrated the promise of splicing modulation therapy as the first radical clinical treatment for FCMD and other SVA-mediated diseases.
Fukuyama muscular dystrophy (FCMD; MIM253800), one of the most common autosomal recessive disorders in Japan, was the first human disease found to result from ancestral insertion of a SINE-VNTR-Alu (SVA) retrotransposon into a causative gene [1] [2] [3] . In FCMD, the SVA insertion occurs in the 39 untranslated region (UTR) of the fukutin gene. The pathogenic mechanism for FCMD is unknown, and no effective clinical treatments exist. Here we show that aberrant messenger RNA (mRNA) splicing, induced by SVA exon-trapping, underlies the molecular pathogenesis of FCMD. Quantitative mRNA analysis pinpointed a region that was missing from transcripts in patients with FCMD. This region spans part of the 39 end of the fukutin coding region, a proximal part of the 39 UTR and the SVA insertion. Correspondingly, fukutin mRNA transcripts in patients with FCMD and SVA knock-in model mice were shorter than the expected length. Sequence analysis revealed an abnormal splicing event, provoked by a strong acceptor site in SVA and a rare alternative donor site in fukutin exon 10. The resulting product truncates the fukutin carboxy (C) terminus and adds 129 amino acids encoded by the SVA. Introduction of antisense oligonucleotides (AONs) targeting the splice acceptor, the predicted exonic splicing enhancer and the intronic splicing enhancer prevented pathogenic exontrapping by SVA in cells of patients with FCMD and model mice, rescuing normal fukutin mRNA expression and protein production. AON treatment also restored fukutin functions, including O-glycosylation of a-dystroglycan (a-DG) and laminin binding by a-DG. Moreover, we observe exon-trapping in other SVA insertions associated with disease (hypercholesterolemia 4 , neutral lipid storage disease 5 ) and human-specific SVA insertion in a novel gene. Thus, although splicing into SVA is known [6] [7] [8] , we have discovered in human disease a role for SVA-mediated exon-trapping and demonstrated the promise of splicing modulation therapy as the first radical clinical treatment for FCMD and other SVA-mediated diseases.
FCMD (incidence 1/34,000 births) shares phenotypic similarities with other severe muscular dystrophies, including muscle-eye-brain disease and Walker-Warburg syndrome. All show deficiencies in O-glycosylation of a-DG, an extracellular protein anchored on the plasma membrane. Insufficient O-glycosylation interferes with the ability of a-DG to interact with extracellular matrix proteins such as laminin 9, 10 . For this reason, FCMD, muscle-eye-brain disease and Walker-Warburg syndrome are categorized as 'a-dystroglycanopathies (a-DGpathy)' 10 ; so far, no effective treatments exist for these conditions. SVA is a hominid-specific, composite non-coding retrotransposon that contains SINE (short interspersed sequence), VNTR (variable number of tandem repeat), and Alu sequences. It is still active in humans, polymorphic and mobilized by the human LINE-1 in trans 6, [11] [12] [13] [14] [15] . In previous work, we showed that fukutin mRNA (10 exons, 7.4-and 6.4-kilobase (kb) cDNAs in size with two poly-A sites, 461-aminoacid protein with calculated molecular mass of 53.7 kDa) was not detectable by northern blot analysis in patients with FCMD carrying the SVA insertion 2 . To investigate the aetiology of this decreased expression, we have now analysed whole fukutin mRNA in lymphoblasts from patients with FCMD using quantitative PCR with reverse transcription (qRT-PCR). PCR products corresponding to the protein-coding region of fukutin, as well as those including sequences in the distal part of the 39 UTR (and thus downstream of the SVA insertion), were similar in abundance to those from an unaffected control (Fig. 1a) . However, products located at sequence positions within the 39 UTR were markedly decreased relative to the control. From these results and along with previous reports of many 39 and 59 splice sites within SVA elements [6] [7] [8] , we hypothesized that abnormal splicing occurs somewhere between the end of the fukutin proteincoding region and the SVA insertion.
We then performed long-range RT-PCR using primers that flank the region corresponding to decreased expression. In patients with FCMD, we detected a single 3-kb PCR product, which is shorter than the 5-kb product seen in the normal control (Fig. 1b) . This observation was consistent in several tissue types from patients with FCMD ( Supplementary Fig. 1 ). PCR from genomic DNA produced an 8-kb product in patients with FCMD, compared with a 5-kb product in the control (Fig. 1b) . Sequence analysis of the 3-kb product from FCMD cDNA revealed a splicing event ( Supplementary Fig. 2 ). This event generates a new donor-side breakpoint within the final coding exon (exon 10), located 116 base pairs (bp) upstream from the authentic stop codon. A rare alternative donor site at that position is activated and trapped by an alternative acceptor site located within the inserted SVA, creating an additional and aberrant exonic sequence (exon 11) (Fig. 1c) . The acceptor-side breakpoint is located 274 bp downstream from the start of the SVA insertion, between ag and TC (Fig. 1c) . The acceptor site has not been described in the previous reports of SVA splicing 6, 7 . This location is preceded by a pyrimidine-rich stretch, the SVA (TCTCCC) 41 hexamer at the 59 end of the SVA element, with a possible favourable branch point. Predicted exonic splicing enhancer sites occur around 70 bp downstream from the new acceptor site. We confirmed that the aberrant splicing event can be abolished by replacing AG with GG at the acceptor junction in cultured cells transfected with a fukutin construct carrying SVA insertion ( Supplementary Fig. 3 ). Fukutin expression was not altered by cycloheximide treatment, indicating that the transcript was not subject to nonsense-mediated mRNA decay, possibly because this exon-trapping occurred within the last exon, and the new stop codon exists downstream of the new last exonexon junction ( Supplementary Fig. 4) .
We have recently generated knock-in mice that carry a humanized fukutin exon 10, which either includes (Hp allele) or excludes (Hn allele) the SVA insertion, and bred these strains with heterozygous fukutin knockout mice to obtain compound heterozygotes (Hp/2) 16 . Knock-in mice that are homozygous (Hp/Hp) and compound heterozygous (Hp/2) are representative of the human FCMD alleles. These mice exhibit hypoglycosylation of a-DG in skeletal muscle, which is the most significant characteristic in a-DGpathy
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. Quantitative RT-PCR in various tissues from Hp/Hp mice revealed an aberrant splicing pattern identical to that seen in human patients ( Supplementary  Fig. 5 ). Northern blot analysis detected abnormally spliced fukutin mRNA species at the expected sizes of 5.6 and 4.6 kb in patients with FCMD, whereas the normal fukutin mRNAs appeared at 7.4 and 6.4 kb ( Fig. 1d and Methods). We replicated these results in the knock-in model mice ( Fig. 1e and Supplementary Fig. 6a ). The consistent observations between patients with FCMD and knock-in model mice lead us to conclude that a splicing abnormality underlies the pathogenesis of FCMD.
Abnormal splicing excises the authentic stop codon and produces another stop codon located 388 bp downstream from the 59 side of the new exon 11 (Fig. 1c) . The predicted protein lacks the C-terminal 38 amino acids of fukutin, instead containing 129 amino acids derived from the SVA sequence ( Supplementary Fig. 7 ). Endogenous fukutin is scarce and difficult to detect; however, we were able to identify both normal and aberrant forms of the protein in human and mouse using immunoprecipitation followed by western blot analysis. The abnormal fukutin protein in FCMD displayed the predicted mobility shift (Fig. 2a-c and Supplementary Fig. 6b ).
We introduced normal and aberrantly spliced fukutin cDNA constructs into mammalian cell lines. Whereas normal fukutin localized to the Golgi apparatus, the aberrantly spliced fukutin protein is displaced completely from the Golgi to the endoplasmic reticulum ( Fig. 2d and Supplementary Fig. 8 ). Further examination showed that a fukutin construct lacking the C-terminal 38 amino acids also mislocalized to the endoplasmic reticulum ( Fig. 2d and Supplementary Fig. 8 ), suggesting that the C-terminal domain of fukutin is important for localization to the Golgi. Thus, impairment of this domain may lead to fukutin dysfunction in FCMD. The mislocalization is unlikely to be toxic because FCMD is an autosomal recessive disease and heterozygous carriers of the SVA insertion have no symptoms.
We next tested if exon-trapping occurs in other diseases with SVA insertion 6 . In a patient with autosomal recessive hypercholesterolemia (ARH), a 2.6-kb SVA was inserted within intron 1 of the LDLRAP1 gene 4 . A patient with lipid storage disease with subclinical myopathy (NLSDM) also had a 1.9-kb SVA insertion in exon 3 of the PNPLA2 gene 5 . We found abnormally spliced products induced by SVA exontrapping in these patients' fibroblast ( 
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that the SVA-trapped transcripts are likely to be subjected to nonsense-mediated mRNA decay 6, 17 . In a search for the same events using the same acceptor site as FCMD in the human genome, we located two expressed sequence tags on human chromosome 4 (DA436529 and DA060755) that represent a spliced transcript induced by an SVA element. We found exonization in a human-specific insertion of SVA (AB627340) into a small gene (Fig. 1f right panel and Supplementary Fig. 11 ). The human-specific exon-trapping of SVA in the small gene might influence human evolution and development.
FCMD alleles of the fukutin gene contain a fully intact protein coding sequence, raising the possibility that FCMD could be treated by restoring translation of the full-length protein through splicing modulation with AONs. To identify promising target sequences in various cell lines, we produced 25-mer 29-O-methyl phosphoramidite (29OMePS) AONs targeted to the acceptor (A1-A3), donor (D1-D5) and exonic splicing enhancer sites (E1-E4) in fukutin pre-mRNA ( Supplementary Fig. 12 ). We introduced the AONs into various cell types and assessed the recovery of normal processing and restoration of the authentic stop codon (Fig. 3a) . Cells with A3 and E3 showed strong suppression of SVA-derived splicing. The greatest recovery of fukutin mRNA, to levels of more than 40% of the normal control, was achieved with a combination of A3, E3 and D5 (AED) (Fig. 3a) . The D5 sequence overlaps with a predicted intronic splicing enhancer site within the aberrant intronic sequence; in normal fukutin, this sequence resides in exon 10 ( Supplementary Fig. 12 ).
We injected octa-guanidine morpholino oligonucleotide (vivomorpholino, VMO) 18 AED cocktail locally into skeletal muscle of knock-in mice and evaluated the therapeutic effect by calculating the percentage recovery of normally processed mRNA. In the AED-treated tibialis anterior and gastrocnemius of Hp/Hp and Hp/2 mice, the amount of corrected fukutin mRNA increased significantly relative to mice treated with control VMO (Fig. 3b and Supplementary Fig. 13 ). We assessed fukutin protein recovery in injected skeletal muscle tissue from Hp/Hp mice. Consistent with the significant increase of restored normal mRNA, normal fukutin protein was rescued (Fig. 4a) . We examined a-DG glycosylation in AED-treated Hp/2 mice. Deficiently glycosylated a-DG, at the predicted smaller size, was reduced in abundance, whereas normal-sized a-DG increased after AED treatment (Fig. 4b) . The signal intensity for glycosylated a-DG was clearly increased, and a shift in the a-DG core was observed, indicating that the rescued fukutin is functional. Laminin overlay assays revealed a marked increase in a-DG laminin-binding ability, indicating that a-DG 
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function also is recovered (Fig. 4b) . We next tested systemic AED treatment by intravenous injection of Hp/2 mice. This treatment also showed the recovery of normally glycosylated a-DG in AED-treated mice (Fig. 4c) .
We administered the VMO AED cocktail to human lymphoblasts and myotubes. As in knock-in mice, we observed successful correction of the splicing abnormality. The corrected fukutin mRNA was restored to 50% or more of the levels seen in normal controls (Fig. 3c) . We believe this to be sufficient recovery, considering that unaffected FCMD carriers have only 50% of normal fukutin mRNA. Finally, we tested recovery of the fukutin protein and the glycosylation of a-DG in the cells of patients with FCMD. Not only was normal fukutin protein expression significantly rescued in AED-treated lymphoblasts (Fig. 4d) , but also we observed recovery of normally glycosylated a-DG in AED-treated myotubes (Fig. 4e) . Immunofluorescence staining also showed immensely increased glycosylated a-DG (Fig. 4f) . A laminin clustering assay showed increased laminin clustering ability, which is characteristically absent in a-DGpathy 19 (Fig. 4f) . These data show that AED treatment effectively rescues normal fukutin, confirming our observation of abnormal fukutin splicing and raising the possibility of splicing modulation therapy as the first treatment for FCMD. To treat neuronal migration disorder of FCMD, prenatal treatment may be necessary, but it is currently difficult for ethical and technical reasons. Nevertheless, improving even only the muscular symptoms would greatly ameliorate quality of life of the patients as well as their families.
Retrotransposons account for nearly half of the human genome 20 . Increased numbers of reports have highlighted positive and negative contributions of retrotransposons to human health and disease 21, 22 . In addition to being the causative factor for FCMD, ARH and NLSDM, SVA insertions have also been implicated in hereditary elliptocytosis, X-linked agammaglobulinemia, neurofibromatosis type 2 and X-linked dystonia-Parkinsonism 12, [23] [24] [25] [26] . It has been suggested that SVA insertions cause such diseases through genomic deletion, reduced mRNA expression or skipping of neighbouring exons 17, 22 . Recently, SVA splicing has been suggested to generate variation within and across species by activating functional 39 splice sites within SVAs across the human genome, controlling gene transcription, creating alternative splicing by exon-trapping, or inducing premature stop codons, and was experimentally demonstrated 6 . Our findings emphasize the importance of SVA functions in human disease and support the possibility of radical treatment against SVA-induced disease by splicing modulation therapy. AONs have become one of the most promising and practical candidate chemicals for splicing modulation therapy in cancer 27 , infectious diseases 28 and Duchenne muscular dystrophy 29, 30 . In demonstrating the ability of AONs to rescue fukutin function in FCMD, we introduce a novel clinical role for them in treating FCMD and other SVA-mediated diseases, while providing new insights about the influence of SVAs on human evolution, development and disease.
METHODS SUMMARY
For AON treatment, 25-mer 29OMePS (GeneDesign and Invitrogen) and octaguanidine morpholino (VMO; Gene-Tools) were used. The knock-in mouse was produced as described previously 16 .
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. 
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METHODS
Antisense oligonucleotides. Twenty-five-mer 29OMePS (GeneDesign and Invitrogen) and VMO oligonucleotides (Gene-Tools) were designed to target potential splice-modulating sequences of SVA-inserted fukutin, including a splicing acceptor site, a splicing donor site, exonic splicing enhancers and intronic splicing enhancers as follows: A1, CCGTGGAAGGAGACTGTGGAGGGAG; A2, GGAGACCGTGGAAGGAGACTGTGGA; A3, AGAGGGAGACCGTGGA AGGAGACTG; E1, CACCGTCCAGCCTTGGCTCGGCATC; E2, CTGCAGTG AGCCGAGATGGCAGCAG; E3, GAGGCAGGAGAATCAGGCAGGGAGG; E4, GAAAACCAGTGAGGCGTAGCAGGCT; D1, CAGGTCTTACCATAGT TGGCTTCAA; D2, CAGGAATCTTCCAGGTCTTACCATA; D3, GAGCGCTT CCAGTCCCACGTCTTTA; D4, TCCATTGGGTTGCACATTGGGAGGA; D5, CATCCCACTCAGAAATAGGCCAGAT; DYS, GGCCAAACCTCGGCTTAC CTGAAAT 31 . U (uracil) was used instead of T (thymine) for the synthesis of 29O-MePS oligonucleotides. Target sequences are shown in Supplementary Fig. 12 . Exonic splicing enhancer sites were predicted by ESEfinder 3.0 (http://rulai.cshl.edu/ cgi-bin/tools/ESE3/esefinder.cgi), and intronic splicing enhancer sites were predicted by ACESCAN2 (http://genes.mit.edu/acescan2/index.html). AONs were solubilized in sterile distilled water. Animals and cells. All mouse experimental protocols were approved by the Ethics Review Committees for Animal Experimentation at Osaka University Graduate School of Medicine and Kobe University Graduate School of Medicine. FCMD knock-in model mice and the mouse nomenclature have been described previously 16 . The transgenic alleles containing normal and SVA-inserted human exon 10 were named Hn and Hp, respectively: Hp/Hp is homozygous for the SVA allele; Hn/Hn is homozygous for the normal allele; Hp/1 and Hp/2 are SVA carriers and compound heterozygotes for the SVA and knockout alleles, respectively. The ages of mice used in experiments varied from 2 to 6 months. The mouse ES cell line carrying the SVA-inserted human genomic fukutin exon 10 was generated from Hp/Hp mice. The ES cell line carrying a fukutin knockout allele has been described previously 32 . The commercially available mouse ES cell line AB2.2 was used as a control. Human lymphoblasts were obtained from patients with FCMD with homozygous SVA insertions and from unaffected individuals. Human primary myoblasts were derived from muscle biopsies from patients with FCMD and unaffected individuals. Human primary fibroblasts were obtained by skin biopsy from patients with ARH and NLSDM. Human autopsy brain samples were obtained from patients with FCMD (fetus and 34-year-old) and DMD (34-yearold). Chimpanzee brain sample was provided by the Great Ape Information Network, Japan. Human brain RNA was purchased from Clontech. All clinical samples were used with the approval of Human Ethics Review Committees of Osaka University Graduate School of Medicine and Kobe University Graduate School of Medicine. Myoblast differentiation. Myoblast cells were maintained at 37 uC and 5% CO 2 in DMEM medium plus 20% fetal bovine serum, 2.5 ng ml 21 of basic fibroblast growth factor (Sigma), and a 0.5% penicillin-streptomycin-amphotericinB mix (Wako). Myotubes were obtained from confluent myoblast cultures after 10-14 days of serum deprivation and replacement with 2% FBS. RNA isolation, RT-PCR, qRT-PCR and sequencing. To inhibit nonsensemediated mRNA decay, cycloheximide (100 mg ml 21 ) (Sigma) was added to the culture medium 24 h before RNA isolation. For RT-PCR and qRT-PCR, total RNA was extracted using the RNeasy Plus Mini kit (Qiagen), and cDNA was obtained using the Superscript III One-step RT-PCR system (Invitrogen) with random primers, following the manufacturer's instructions. SYBR Pre-mix Ex Taq (Takara) was used for qRT-PCR, and expression values were normalized to gapdh as an internal control for mRNA quantity. Data were obtained from triplicate experiments. To detect abnormally spliced RT-PCR products from patients with FCMD, ARH and NLSDM, and from human brain AB627340 cDNA, long-range PCR was performed using LA Taq with LA Taq Buffer II (Takara), adding dimethyl sulphoxide and 7-deaza-dGTP (Roche). The RT-PCR products were directly sequenced (FCMD and NLSDM), or cloned with the TOPO TA Cloning Kit (Invitrogen) before sequencing (ARH and AB627340). To calculate the expression ratio in Fig. 1a and Supplementary Figs 4, 5, 9, 10 and 13, the value in the mutant sample was divided by the value in the normal sample, as measured by qRT-PCR. To identify AON target sequences, we designed three primers to distinguish recovered transcripts from unrecovered transcripts by AON treatment (Fig. 3a) . Similarly, we designed three primers to compare expression amount of SVA-trapped to SVA-untrapped transcripts of the AB627340 gene (Supplementary Fig. 11a) . One primer on SVA in Fig. 3a and Supplementary Fig. 11a was within Alu-like domain: the sequence was 59-GAAAACCAGTGAGGCGTAGC-39. To calculate the percentage recovery of normal mRNA processing in Fig. 3b, c and Supplementary Fig. 13 , the value of treated sample was divided by that of normal samples, as measured by qRT-PCR at sequence position 1341, where the authentic stop codon resides. Primer sequences for qRT-PCR and RT-PCR are available upon request. Northern blot analysis. Previous attempts to detect fukutin mRNA in patients with FCMD by northern blot analysis have been unsuccessful 2 , probably because the predicted mRNA sequence is the same size as abundant ribosomal RNA. Moreover, the tertiary structure of fukutin mRNA is presumably complicated owing to the immensely GC-rich SVA sequence. Therefore, we performed northern blot analysis of FCMD and control mRNA after treatment to remove abundant ribosomal RNA and strong denaturation to untangle the fukutin transcript. Total RNA (1 mg) was extracted from human lymphoblasts, mouse ES cells, mouse brain and mouse skeletal muscle using TRIzol (Invitrogen). Oligotex-dT30,Super. (Takara) was used to extract more than 3 mg of poly-A RNA. Ribosomal RNA was removed using Ribo-Minus (Invitrogen). Stronger denaturation of RNA was achieved by incubating polyA-RNA samples with a combination of 0.8 M glyoxal and 50% DMSO in 10 mM sodium phosphate buffer (pH 7.0) for 60 min at 55 uC. Three micrograms of poly-A RNA was loaded on the agarose gel. A fukutin cDNA clone covering the fukutin coding sequence was 32 P-labelled and used as a probe. cDNA expression constructs. The normal fukutin cDNA encodes full-length fukutin protein. The spliced fukutin construct encodes abnormal fukutin, as shown in Supplementary Fig. 7 . The truncated fukutin construct lacks the C-terminal 38 amino acids. All constructs encoded FLAG epitope tags fused to the C terminus of the expressed protein.
Cell transfection. HeLa S3 cells and C2C12 cells were transfected with normal fukutin construct, spliced fukutin construct and truncated fukutin construct using FuGENE 6 (Roche). Fukutin localization was determined using immunocytochemistry 2 days after transfection. For transfection of AONs, 29OMePS were introduced into various cell lines, including mouse ES cells, human myoblasts and human lymphoblasts, using Lipofectin (Invitrogen). Detection of endogenous fukutin protein. The polyclonal rabbit anti-fukutin antibody RY213 recognizes the peptide CLKIESKDPRLDGIDS, and the polyclonal goat-anti-fukutin antibody 106G2 recognizes full-length fukutin protein lacking the amino (N)-terminal hydrophobic domain. Endogenous fukutin was detected by immunoprecipitation using 106G2, from cell or tissue lysates containing 5-10 mg of total protein in lysis buffer (1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 20 mM Tris-Cl, pH 7.5 and 150 mM NaCl), followed by western blot analysis using affinity-purified RY213.
Immunofluorescence and western blot analysis. Cells were washed and fixed with 4% paraformaldehyde in PBS. The following primary antibodies were used: anti-GM130 (monoclonal, BD Bioscience), anti-KDEL (monoclonal, Stressgen), anti-FLAG (rabbit polyclonal, MBL), anti-a-DG (monoclonal, IIH6C4 and VIA4-1, Millipore) and anti-laminin (rabbit polyclonal, Sigma). To stain nuclei, 496-diamidino-2-phenylindole (DAPI, Sigma) was added to the secondary antibody solution at a final concentration of 1 ng ml 21 . Cells were observed under fluorescence confocal microscopy (Carl Zeiss). Western blot analysis and laminin overlay assays were performed as described previously 16 . Mutagenesis analysis. We made the four fukutin constructs: pHn, human normal fukutin construct consisting of exon 2-9 cDNA and genomic normal exon 10; pHp, patient fukutin construct consisting of exon 2-9 cDNA and genomic patient exon 10 with SVA insertion; pSpl, patient fukutin construct pHp, which lacks the abnormally spliced region; pAcc, patient fukutin construct pHp with AG to GG replacement at the acceptor site within the SVA sequence. These constructs were transfected into HeLa S3 cells using Effectene (Qiagen). After extraction of poly-A RNA by Oligotex, northern blot analysis was performed using 2 mg of poly-A RNA for each sample with stronger denaturation mentioned above. AON treatment of FCMD model mice. For intramuscular injection, we injected cardiotoxin (10 mM) (Latoxan) percutaneously into tibialis anterior (0.3 nmol) and gastrocnemius (0.7 nmol) of Hp/1, Hp/2, Hp/Hp and Hn/Hn mice on day 0 (n 5 3 for each genotype). On days 1, 4 and 7, VMO (400 mg kg
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) solubilized in sterile distilled water was injected. AED and Dys were administered to the left and the right legs, respectively. For systemic injection, an intraperitoneal injection of butorphanol tartrate (5 mg kg 21 ) (Bristol-Myers Squibb) was performed on day 0. VMO (20 mg kg 21 ) solubilized in 5% glucose solution was administered by intravenous injection through the tail vein on days 1 and 7 (n 5 4 for Hp/2, n 5 2 for Hp/1). Mice were killed on day 21, and total RNA or protein lysate was isolated from each tissue for further analyses of fukutin mRNA expression, fukutin protein translation, and glycosylation of a-DG. AON treatment of human patient cell lines. For protein analysis, VMO cocktails (AED and Dys) were introduced into FCMD and normal control lymphoblasts at a final concentration of 2.5 mM in culture medium using a Gene Pulser II Electroporator (0.25-kV voltage, 960-mF capacitance, with 0.4-cm gene pulser cuvettes, giving a time-constant readout of approximately 40 ms) (Bio-Rad) (n 5 2). For glycosylation analysis, VMO cocktails (AED and Dys) were introduced into myoblasts from patients with FCMD and normal control cells by direct RESEARCH LETTER
